{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:23Z","timestamp":1790812103664,"version":"4.1.0"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3597,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anxiety disorders are common and often disabling. They fall into five main categories: panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder and posttraumatic stress disorder, each of which have characteristic symptoms and cognitions. All anxiety disorders respond to drugs and psychological treatments. This review will focus on drug treatments. Recent research has emphasized the value of antidepressants especially the selective serotonin reuptake inhibitors, benzodiazepines, and related sedative-like compounds. The common co-existence of depression with all of the anxiety disorders means that the selective serotonin reuptake inhibitors are now generally considered to be the first-line treatments but the benzodiazepines have some utility especiaRy in promoting sleep and working acutely to reduce extreme distress.<\/jats:p>","DOI":"10.1017\/s1092852900009901","type":"journal-article","created":{"date-parts":[[2016,1,3]],"date-time":"2016-01-03T22:16:27Z","timestamp":1451859387000},"page":"49-56","source":"Crossref","is-referenced-by-count":151,"title":["Overview of Diagnosis and Drug Treatments of Anxiety Disorders"],"prefix":"10.1017","volume":"10","author":[{"given":"David J.","family":"Nutt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900009901_ref037","doi-asserted-by":"publisher","DOI":"10.1177\/026988119500900202"},{"key":"S1092852900009901_ref020","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600412"},{"key":"S1092852900009901_ref008","volume-title":"Task Force Report of the American Psychiatric Association","year":"1990"},{"key":"S1092852900009901_ref034","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.19.2529"},{"key":"S1092852900009901_ref031","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950040053007"},{"key":"S1092852900009901_ref012","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"Br J Gen Pract"},{"key":"S1092852900009901_ref004","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000329"},{"key":"S1092852900009901_ref033","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702006876"},{"key":"S1092852900009901_ref038","first-page":"1136","article-title":"Cognitive enhancers and adjuncts to psychotherapy: use of D-cycloserine in phobics to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Psychopharmacobgy (Berl)"},{"key":"S1092852900009901_ref013","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000138764.31106.60"},{"key":"S1092852900009901_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00014-1"},{"key":"S1092852900009901_ref026","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1112"},{"key":"S1092852900009901_ref018","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4921-03.2004"},{"key":"S1092852900009901_ref015","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464040-00004"},{"key":"S1092852900009901_ref011","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500102"},{"key":"S1092852900009901_ref036","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4927(98)00041-9"},{"key":"S1092852900009901_ref022","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000117423.05703.e7"},{"key":"S1092852900009901_ref021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0418"},{"key":"S1092852900009901_ref035","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.5.425"},{"key":"S1092852900009901_ref032","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.2.174"},{"key":"S1092852900009901_ref016","doi-asserted-by":"publisher","DOI":"10.1038\/416396a"},{"key":"S1092852900009901_ref025","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103017002004"},{"key":"S1092852900009901_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.8.715"},{"key":"S1092852900009901_ref001","volume-title":"Anxiety Disorders","author":"Nutt","year":"2003"},{"key":"S1092852900009901_ref017","first-page":"A30","article-title":"Altered 5HT1A binding in panic disorder demonstrated by PET scanning","volume":"17","author":"Nash","year":"2003","journal-title":"J Psychopharmacology"},{"key":"S1092852900009901_ref024","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0401"},{"key":"S1092852900009901_ref006","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.5.361"},{"key":"S1092852900009901_ref019","doi-asserted-by":"publisher","DOI":"10.1177\/026988119801200401"},{"key":"S1092852900009901_ref029","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600116"},{"key":"S1092852900009901_ref005","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00188-2"},{"key":"S1092852900009901_ref010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00245.x"},{"key":"S1092852900009901_ref023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0301"},{"key":"S1092852900009901_ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.07.006"},{"key":"S1092852900009901_ref002","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.6.465"},{"key":"S1092852900009901_ref007","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174019"},{"key":"S1092852900009901_ref014","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v01n0502"},{"key":"S1092852900009901_ref009","volume-title":"Practice Guidelines for the Treatment of Patients with Panic Disorder","year":"1998"},{"key":"S1092852900009901_ref027","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050731"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900009901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T15:20:13Z","timestamp":1557156013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900009901\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S1092852900009901"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900009901","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}